- Home
- GCTS vs RIGL Comparison
GCTS vs RIGL Comparison
Compare GCTS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTS
- RIGL
- Stock Information
- Founded
- GCTS 1998
- RIGL 1996
- Country
- GCTS United States
- RIGL United States
- Employees
- GCTS N/A
- RIGL N/A
- Industry
- GCTS Blank Checks
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- GCTS Finance
- RIGL Health Care
- Exchange
- GCTS Nasdaq
- RIGL Nasdaq
- Market Cap
- GCTS 82.5M
- RIGL 335.5M
- IPO Year
- GCTS N/A
- RIGL 2000
- Fundamental
- Price
- GCTS $1.46
- RIGL $18.93
- Analyst Decision
- GCTS Strong Buy
- RIGL Buy
- Analyst Count
- GCTS 1
- RIGL 5
- Target Price
- GCTS $5.00
- RIGL $36.40
- AVG Volume (30 Days)
- GCTS 999.8K
- RIGL 196.7K
- Earning Date
- GCTS 08-13-2025
- RIGL 08-05-2025
- Dividend Yield
- GCTS N/A
- RIGL N/A
- EPS Growth
- GCTS N/A
- RIGL N/A
- EPS
- GCTS N/A
- RIGL 2.08
- Revenue
- GCTS $6,359,000.00
- RIGL $203,077,000.00
- Revenue This Year
- GCTS $133.55
- RIGL $14.41
- Revenue Next Year
- GCTS $347.37
- RIGL $15.97
- P/E Ratio
- GCTS N/A
- RIGL $9.09
- Revenue Growth
- GCTS N/A
- RIGL 70.16
- 52 Week Low
- GCTS $0.90
- RIGL $7.48
- 52 Week High
- GCTS $5.45
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- GCTS 52.78
- RIGL 44.97
- Support Level
- GCTS $1.41
- RIGL $18.24
- Resistance Level
- GCTS $1.53
- RIGL $19.35
- Average True Range (ATR)
- GCTS 0.13
- RIGL 0.90
- MACD
- GCTS 0.01
- RIGL -0.14
- Stochastic Oscillator
- GCTS 30.50
- RIGL 23.44
About GCTS GCT Semiconductor Holding Inc. Common Stock
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.